A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma

Forty-eight patients with advanced breast carcinoma who had not received prior chemotherapy (minimum follow up 21 months) were randomised to receive either adriamycin 70 mg m-2 i.v. 3-weekly for 8 cycles (Regimen A) or adriamycin 35 mg m-2 i.v. 3-weekly for 16 courses (Regimen B). Objective response...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of cancer Vol. 56; no. 4; pp. 471 - 473
Main Authors Carmo-Pereira, J, Costa, F O, Henriques, E, Godinho, F, Cantinho-Lopes, M G, Sales-Luis, A, Rubens, R D
Format Journal Article
LanguageEnglish
Published England Nature Publishing Group 01.10.1987
Subjects
Adult
Aged
Breast Neoplasms - drug therapy
Clinical Trials as Topic
Doxorubicin - administration & dosage
Doxorubicin - therapeutic use
Drug Administration Schedule
Female
Humans
Middle Aged
Random Allocation
Time Factors
Online AccessGet full text

Cover

More Information
Summary:Forty-eight patients with advanced breast carcinoma who had not received prior chemotherapy (minimum follow up 21 months) were randomised to receive either adriamycin 70 mg m-2 i.v. 3-weekly for 8 cycles (Regimen A) or adriamycin 35 mg m-2 i.v. 3-weekly for 16 courses (Regimen B). Objective responses were seen in 14/24 (58%) patients with regimen A (4 complete) and 6/24 (25%) with regimen B (1 complete) (P less than 0.02). The median duration of response was 14 months with regimen A and 6.5 months with regimen B. The median duration of survival was 20 months and 8 months respectively (P less than 0.01). The toxicity was similar with each regimen. There was no evidence of deterioration in left ventricular ejection fraction nor congestive heart failure in any patient. It is concluded that when given at 3-weekly intervals adriamycin is a more effective treatment for advanced breast cancer at higher rather than lower dosage.
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.1987.226